InvestorsHub Logo
Followers 23
Posts 2120
Boards Moderated 0
Alias Born 06/21/2015

Re: None

Wednesday, 10/12/2016 5:11:41 PM

Wednesday, October 12, 2016 5:11:41 PM

Post# of 462739
CTAD 2016

8.45 a.m OC59 - 9-Months and 12-Months Safety and Exploratory Efficacy Data of ANAVEX 2-73 in a Phase 2a Study
in Mild-to-Moderate Alzheimer’s Disease Patients
Stephen Macfarlane, MD1, Marco Cecchi, PhD2, Paul Maruff, PhD3 , Kristina M Kapiak4, Christopher U Missling, PhD4
(1) Caulfield Hospital, Melbourne, Australia, (2) Neuronetrix, Louisville, KY, USA, (3) Cogstate Ltd., Melbourne, Australia, (4) Anavex Life Sciences Corp., New York, NY,
USA
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News